Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins

References

• 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2020;16(3):391–460. Pubmed: https://pubmed.ncbi.nlm.nih.gov/32157811/
   Google Scholar
• Bekris LM, Yu CE, Bird TD, et al. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–227.
   PubMed Web of Science ®Google Scholar
• Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference? Neurol Genet. 2020;6(5):e512.
   PubMed Web of Science ®Google Scholar
• Schmidt ML, Robinson KA, Lee VM, et al. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer’s disease and Down’s syndrome brains revealed by confocal microscopy. Am J Pathol. 1995;147(2):503–515.
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc. 2006;1(3):1591–1595.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dementia. 2018;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Walker LC, Lynn DG, Chernoff YO. A standard model of Alzheimer’s disease? Prion. 2018;12(5–6):261–265.
   PubMed Web of Science ®Google Scholar
• Luo J, Agboola F, Grant E, et al. Sequence of Alzheimer disease biomarker changes in cognitively normal adults: a cross-sectional study. Neurology. 2020;95(23):e3104–e3116.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34(7):939–944.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7(3):257–262. .
   PubMed Web of Science ®Google Scholar
• Hubbard BM, Fenton GW, Anderson JM. A quantitative histological study of early clinical and preclinical Alzheimer’s disease. Neuropathol Appl Neurobiol. 1990;16(2):111–121.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7(3):280–292.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dementia. 2011;7(3):270–279.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7(3):263–269.
   PubMed Web of Science ®Google Scholar
• Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimer’s Dementia. 2019;15(7):888–898.
   PubMed Web of Science ®Google Scholar
• Mantile F, Prisco A. Vaccination against beta-amyloid as a strategy for the prevention of Alzheimer’s disease. Biology (Basel). 2020;9(12):425. doi:https://doi.org/10.3390/biology9120425
   Google Scholar
• Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6(1):e12050.
   PubMedGoogle Scholar
• Zissimopoulos J, Crimmins E, St Clair P. The value of delaying Alzheimer’s disease onset. Forum Health Econ Policy. 2014;18(1):25–39.
   PubMedGoogle Scholar
• Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245–4249.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol. 1994;10:373–403.
   PubMedGoogle Scholar
• Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature. 1999;399(6738 Suppl):A23–31.
   PubMed Web of Science ®Google Scholar
• Wolfe MS. Structure and function of the gamma-secretase complex. Biochemistry. 2019;58(27):2953–2966.
   PubMed Web of Science ®Google Scholar
• Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer’s beta-peptide from biological fluids. Nature. 1992;359(6393):325–327.
   PubMed Web of Science ®Google Scholar
• Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol. 1995;38(4):643–648. .
   PubMed Web of Science ®Google Scholar
• Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652–656.
   PubMed Web of Science ®Google Scholar
• Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.
   PubMed Web of Science ®Google Scholar
• Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512–519.
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Mattsson N, Hansson O, et al. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139(Pt 4):1226–1236.
   PubMedGoogle Scholar
• Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci. 1998;158(2):134–140.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging. 2004;25(3):273–281.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–663.
   PubMed Web of Science ®Google Scholar
• Hansson O, Lehmann S, Otto M, et al. Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther. 2019;11(1):34.
   PubMedGoogle Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913–4917.
   PubMed Web of Science ®Google Scholar
• Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2(7):a006247.
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–684.
   PubMed Web of Science ®Google Scholar
• Skillback T, Rosen C, Asztely F, et al. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish mortality registry. JAMA Neurol. 2014;71(4):476–483.
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187–190.
   PubMed Web of Science ®Google Scholar
• Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457–468.
   PubMed Web of Science ®Google Scholar
• Mattsson N, Scholl M, Strandberg O, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017;9(9):1212–1223.
   PubMed Web of Science ®Google Scholar
• Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer’s Dementia. 2018;14(11):1460–1469.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Otto MA. Review on MS-based blood biomarkers for Alzheimer’s disease. Neurol Ther. 2019;8(Suppl 2):113–127.
   PubMed Web of Science ®Google Scholar
• Penner G, Lecocq S, Chopin A, et al. Blood-based diagnostics of Alzheimer’s disease. Expert Rev Mol Diagn. 2019;19(7):613–621.
   PubMed Web of Science ®Google Scholar
• Wang M, Qin L, Tang B. microRNAs in Alzheimer’s disease. Front Genet. 2019;10:153.
   PubMed Web of Science ®Google Scholar
• Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698–712.
   PubMed Web of Science ®Google Scholar
• Aisen PS. Editorial: failure after failure. What next in AD drug development? J Prev Alzheimers Dis. 2019;6(3):150.
   PubMed Web of Science ®Google Scholar
• Hu S, Loo JA, Wong DT. Human body fluid proteome analysis. Proteomics. 2006;6(23):6326–6353.
   PubMed Web of Science ®Google Scholar
• Huang Y, Potter R, Sigurdson W, et al. beta-amyloid dynamics in human plasma. Arch Neurol. 2012;69(12):1591–1597.
   PubMedGoogle Scholar
• Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595–599.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Mortberg E, Song L, et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PLoS One. 2011;6(12):e28263.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Stomrud E, Palmqvist S, et al. Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6:26801.
   PubMed Web of Science ®Google Scholar
• Pannee J, Tornqvist U, Westerlund A, et al. The amyloid-beta degradation pattern in plasma–a possible tool for clinical trials in Alzheimer’s disease. Neurosci Lett. 2014;573:7–12.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249–254.
   PubMed Web of Science ®Google Scholar
• Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647–e1659.
   PubMed Web of Science ®Google Scholar
• Barthelemy NR, Mallipeddi N, Moiseyev P, et al. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer’s disease. Front Aging Neurosci. 2019;11:121.
   PubMed Web of Science ®Google Scholar
• Barthelemy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12(1):26.
   PubMed Web of Science ®Google Scholar
• Barthelemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med. 2020;26(3):398–407.
   PubMed Web of Science ®Google Scholar
• Barthelemy NR, Horie K, Sato C, et al. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020; 217(11): e20200861.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106(10):4012–4017.
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101–112.
   PubMed Web of Science ®Google Scholar
• Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66(2):190–199.
   PubMedGoogle Scholar
• Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–298.
   PubMed Web of Science ®Google Scholar
• Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810–813.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Moore RA, Sim VL, et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods. 2007;4(8):645–650.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Wilham JM, Christensen L, et al. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods. 2008;5(3):211–212.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17(2):175–178.
   PubMed Web of Science ®Google Scholar
• Biancalana M, Makabe K, Koide A, et al. Molecular mechanism of thioflavin-T binding to the surface of beta-rich peptide self-assemblies. J Mol Biol. 2009;385(4):1052–1063.
   PubMed Web of Science ®Google Scholar
• Erana H, Charco JM, Gonzalez-Miranda E, et al. Detection of pathognomonic biomarker PrP(Sc) and the contribution of cell free-amplification techniques to the diagnosis of Prion diseases. Biomolecules. 2020;10(3):469.
   Web of Science ®Google Scholar
• Green AJE. RT-QuIC: a new test for sporadic CJD. Pract Neurol. 2019;19(1):49–55.
   PubMedGoogle Scholar
• Edgeworth JA, Farmer M, Sicilia A, et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet. 2011;377(9764):487–493.
   PubMed Web of Science ®Google Scholar
• Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med. 2014;371(6):530–539.
   PubMed Web of Science ®Google Scholar
• Orru CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371(6):519–529.
   PubMed Web of Science ®Google Scholar
• Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812–818.
   PubMed Web of Science ®Google Scholar
• Salvadores N, Shahnawaz M, Scarpini E, et al. Detection of misfolded Abeta oligomers for sensitive biochemical diagnosis of Alzheimer’s disease. Cell Rep. 2014;7(1):261–268.
   PubMed Web of Science ®Google Scholar
• Estrada LD, Chamorro D, Yanez MJ, et al. Reduction of blood Amyloid-beta oligomers in Alzheimer’s disease transgenic Mice by c-Abl kinase inhibition. J Alzheimers Dis. 2016;54(3):1193–1205.
   PubMed Web of Science ®Google Scholar
• Wang MJ, Yi S, Han JY, et al. Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimers Res Ther. 2017;9(1):98.
   PubMedGoogle Scholar
• An SSA, Lee BS, Yu JS, et al. Dynamic changes of oligomeric amyloid beta levels in plasma induced by spiked synthetic Abeta42. Alzheimers Res Ther. 2017;9(1):86.
   PubMedGoogle Scholar
• Youn YC, Lee BS, Kim GJ, et al. Blood amyloid-beta oligomerization as a biomarker of Alzheimer’s disease: a blinded validation study. J Alzheimers Dis. 2020;75(2):493–499.
   PubMed Web of Science ®Google Scholar
• Consensus report of the Working Group on. “Molecular and biochemical markers of Alzheimer’s disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19(2):109–116.
   PubMed Web of Science ®Google Scholar